Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in J Immunol

Retrieve available abstracts of 19 articles:
HTML format



Single Articles


    September 2021
  1. LI Z, Gao Y, He C, Wei H, et al
    Purinergic Receptor P2Y6 Is a Negative Regulator of NK Cell Maturation and Function.
    J Immunol. 2021;207:1555-1565.
    PubMed     Abstract available


  2. OROZCO RC, Marquardt K, Mowen K, Sherman LA, et al
    Proautoimmune Allele of Tyrosine Phosphatase, PTPN22, Enhances Tumor Immunity.
    J Immunol. 2021;207:1662-1671.
    PubMed     Abstract available


  3. ISLAM A, Pishesha N, Harmand TJ, Heston H, et al
    Converting an Anti-Mouse CD4 Monoclonal Antibody into an scFv Positron Emission Tomography Imaging Agent for Longitudinal Monitoring of CD4(+) T Cells.
    J Immunol. 2021;207:1468-1477.
    PubMed     Abstract available


    April 2021
  4. CHEN CW, Bennion KB, Swift DA, Morrow KN, et al
    Tumor-Specific T Cells Exacerbate Mortality and Immune Dysregulation during Sepsis.
    J Immunol. 2021 Apr 28. pii: jimmunol.2000865. doi: 10.4049/jimmunol.2000865.
    PubMed     Abstract available


    March 2021
  5. SINGH S, Xiao Z, Bavisi K, Roszik J, et al
    IL-1alpha Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma.
    J Immunol. 2021 Mar 15. pii: jimmunol.2000523. doi: 10.4049/jimmunol.2000523.
    PubMed     Abstract available


    January 2021
  6. O'CONNELL P, Hyslop S, Blake MK, Godbehere S, et al
    SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment.
    J Immunol. 2021;206:193-205.
    PubMed     Abstract available


    October 2020
  7. OBA T, Hoki T, Yamauchi T, Keler T, et al
    A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells.
    J Immunol. 2020;205:1867-1877.
    PubMed     Abstract available


    July 2020
  8. TUCKER CG, Mitchell JS, Martinov T, Burbach BJ, et al
    Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
    J Immunol. 2020 Jul 31. pii: jimmunol.2000007. doi: 10.4049/jimmunol.2000007.
    PubMed     Abstract available


    April 2020
  9. WILSKI NA, Stotesbury C, Del Casale C, Montoya B, et al
    STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.
    J Immunol. 2020 Apr 13. pii: jimmunol.1901136. doi: 10.4049/jimmunol.1901136.
    PubMed     Abstract available


  10. RAUSCH MP, Meador LR, Metzger TC, Li H, et al
    GILT in Thymic Epithelial Cells Facilitates Central CD4 T Cell Tolerance to a Tissue-Restricted, Melanoma-Associated Self-Antigen.
    J Immunol. 2020 Apr 8. pii: jimmunol.1900523. doi: 10.4049/jimmunol.1900523.
    PubMed     Abstract available


    February 2020
  11. RAMIREZ-MORENO IG, Ibarra-Sanchez A, Castillo-Arellano JI, Blank U, et al
    Mast Cells Localize in Hypoxic Zones of Tumors and Secrete CCL-2 under Hypoxia through Activation of L-Type Calcium Channels.
    J Immunol. 2020;204:1056-1068.
    PubMed     Abstract available


    January 2020
  12. BALLY APR, Neeld DK, Lu P, Majumder P, et al
    PD-1 Expression during Acute Infection Is Repressed through an LSD1-Blimp-1 Axis.
    J Immunol. 2020;204:449-458.
    PubMed     Abstract available


    October 2019
  13. BUETOW KH, Meador LR, Menon H, Lu YK, et al
    High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.
    J Immunol. 2019 Oct 7. pii: jimmunol.1900476. doi: 10.4049/jimmunol.1900476.
    PubMed     Abstract available


    June 2019
  14. GANDHAPUDI SK, Ward M, Bush JPC, Bedu-Addo F, et al
    Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response.
    J Immunol. 2019;202:3524-3536.
    PubMed     Abstract available


  15. DANAHY DB, Kurup SP, Winborn CS, Jensen IJ, et al
    Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.
    J Immunol. 2019 Jun 12. pii: jimmunol.1900435. doi: 10.4049/jimmunol.1900435.
    PubMed     Abstract available


    April 2019
  16. DANAHY DB, Jensen IJ, Griffith TS, Badovinac VP, et al
    Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival.
    J Immunol. 2019 Apr 10. pii: jimmunol.1900076. doi: 10.4049/jimmunol.1900076.
    PubMed     Abstract available


    February 2019
  17. ERIKSSON E, Milenova I, Wenthe J, Moreno R, et al
    IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-beta, Collagen Type I, and PD-L1/PD-1.
    J Immunol. 2019;202:787-798.
    PubMed     Abstract available


  18. SALERNO F, Freen-van Heeren JJ, Guislain A, Nicolet BP, et al
    Costimulation through TLR2 Drives Polyfunctional CD8(+) T Cell Responses.
    J Immunol. 2019;202:714-723.
    PubMed     Abstract available


  19. LEE CC, Ding X, Zhao T, Wu L, et al
    Transthyretin Stimulates Tumor Growth through Regulation of Tumor, Immune, and Endothelial Cells.
    J Immunol. 2019;202:991-1002.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: